Swiss pharmaceutical company Novartis says it is not yet ready to resume production at its facility in Lincoln.
The plant is unlikely to ship over-the-counter drugs before year's end. The company said in a statement Thursday that restarting production is taking longer than expected.
At least one over-the-counter product, Excedrin, started hitting shelves again within the past week, but the company says it is being manufactured at third-party sites.
Novartis shut down the Lincoln plant last December after federal inspections found numerous quality-control problems. Excedrin is one of many products from the Lincoln plant that have been out of stock since the plant shut down. Others include Bufferin, NoDoz, Gas-X, Triaminic, Lamisil and Theraflu.